Shanghai ZJ Bio-Tech Co (SHSE:688317) Piotroski F-Score: 6 (As of Jun. 25, 2026) — 20% Above Median


SHSE:688317 Shanghai ZJ Bio-Tech Co Ltd SHSE:688317
68 GF Score
Price ¥15.68
GF Value ¥9.94
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Shanghai ZJ Bio-Tech Co Piotroski F-Score?

Shanghai ZJ Bio-Tech Co SHSE:688317 -4.33% 68 Piotroski F-Score is 6 as of Jun. 25, 2026, which is 20% above its 10-year median of 5.00. GuruFocus rates SHSE:688317 with a GF Score™ of 68/100 and a GF Value™ of ¥9.94 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 805 Medical Devices & Instruments companies, Shanghai ZJ Bio-Tech Co ranks better than 80.87% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Shanghai ZJ Bio-Tech Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Shanghai ZJ Bio-Tech Co's Piotroski F-Score or its related term are showing as below:

SHSE:688317' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 5   Max: 7
Current: 6

During the past 13 years, the highest Piotroski F-Score of Shanghai ZJ Bio-Tech Co was 7. The lowest was 2. And the median was 5.

Shanghai ZJ Bio-Tech Co  (SHSE:688317) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Shanghai ZJ Bio-Tech Co Piotroski F-Score Related Terms


Shanghai ZJ Bio-Tech Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Shanghai ZJ Bio-Tech Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai ZJ Bio-Tech Co Piotroski F-Score Chart

Shanghai ZJ Bio-Tech Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 2.00 5.00 4.00 6.00

Shanghai ZJ Bio-Tech Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 3.00 5.00 6.00 6.00

SHSE:688317 vs ABT, SYK, MDT: Piotroski F-Score Comparison

For the Medical Devices subindustry, Shanghai ZJ Bio-Tech Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai ZJ Bio-Tech Co Piotroski F-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Shanghai ZJ Bio-Tech Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Shanghai ZJ Bio-Tech Co's Piotroski F-Score falls into.


SHSE:688317
68GF Score
Shanghai ZJ Bio-Tech Co Ltd SHSE:688317
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 6.166 + -19.527 + -4.92 + -25.51 = ¥-43.8 Mil.
Cash Flow from Operations was 23.823 + 6.848 + 34.181 + -3.66 = ¥61.2 Mil.
Revenue was 27.548 + 30.75 + 34.386 + 25.419 = ¥118.1 Mil.
Gross Profit was 17.256 + 18.697 + 23.441 + 17.503 = ¥76.9 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(3773.525 + 3778.489 + 3721.102 + 3763.8 + 3706.727) / 5 = ¥3748.7286 Mil.
Total Assets at the begining of this year (Mar25) was ¥3,773.5 Mil.
Long-Term Debt & Capital Lease Obligation was ¥287.0 Mil.
Total Current Assets was ¥2,914.2 Mil.
Total Current Liabilities was ¥115.7 Mil.
Net Income was -0.902 + -39.015 + -114.453 + -16.017 = ¥-170.4 Mil.

Revenue was 43.369 + 42.984 + 41.072 + 32.135 = ¥159.6 Mil.
Gross Profit was 31.772 + 29.067 + 9.277 + 20.681 = ¥90.8 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(4044.481 + 3996.487 + 3936.48 + 3789.95 + 3773.525) / 5 = ¥3908.1846 Mil.
Total Assets at the begining of last year (Mar24) was ¥4,044.5 Mil.
Long-Term Debt & Capital Lease Obligation was ¥102.1 Mil.
Total Current Assets was ¥2,931.4 Mil.
Total Current Liabilities was ¥136.9 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Shanghai ZJ Bio-Tech Co's current Net Income (TTM) was -43.8. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Shanghai ZJ Bio-Tech Co's current Cash Flow from Operations (TTM) was 61.2. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-43.791/3773.525
=-0.0116048

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-170.387/4044.481
=-0.04212827

Shanghai ZJ Bio-Tech Co's return on assets of this year was -0.0116048. Shanghai ZJ Bio-Tech Co's return on assets of last year was -0.04212827. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Shanghai ZJ Bio-Tech Co's current Net Income (TTM) was -43.8. Shanghai ZJ Bio-Tech Co's current Cash Flow from Operations (TTM) was 61.2. ==> 61.2 > -43.8 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=286.985/3748.7286
=0.07655529

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=102.09/3908.1846
=0.0261221

Shanghai ZJ Bio-Tech Co's gearing of this year was 0.07655529. Shanghai ZJ Bio-Tech Co's gearing of last year was 0.0261221. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=2914.156/115.705
=25.1860853

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=2931.381/136.916
=21.41006895

Shanghai ZJ Bio-Tech Co's current ratio of this year was 25.1860853. Shanghai ZJ Bio-Tech Co's current ratio of last year was 21.41006895. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Shanghai ZJ Bio-Tech Co's number of shares in issue this year was 170.068. Shanghai ZJ Bio-Tech Co's number of shares in issue last year was 200.217. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=76.897/118.103
=0.65110116

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=90.797/159.56
=0.56904613

Shanghai ZJ Bio-Tech Co's gross margin of this year was 0.65110116. Shanghai ZJ Bio-Tech Co's gross margin of last year was 0.56904613. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=118.103/3773.525
=0.03129779

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=159.56/4044.481
=0.03945129

Shanghai ZJ Bio-Tech Co's asset turnover of this year was 0.03129779. Shanghai ZJ Bio-Tech Co's asset turnover of last year was 0.03945129. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+1+1+0+1+1+1+0
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Shanghai ZJ Bio-Tech Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 6 mean?
Shanghai ZJ Bio-Tech Co (SHSE:688317) has a Piotroski F-Score of 6 as of Jun. 25, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Shanghai ZJ Bio-Tech Co and its competitors. This is 20% above median its historical median of 5.00. Over the past decade, Shanghai ZJ Bio-Tech Co's Piotroski F-Score has ranged from 2.00 to 7.00. According to the industry distribution chart, Shanghai ZJ Bio-Tech Co ranks #154 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 19.1%.
Is Shanghai ZJ Bio-Tech Co's Piotroski F-Score too high?
Shanghai ZJ Bio-Tech Co's current Piotroski F-Score of 6 is 20% above median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 7.00. The Medical Devices & Instruments industry median Piotroski F-Score is 5.00. Shanghai ZJ Bio-Tech Co's value of 6 is 20% above this industry median. Based on the distribution chart, Shanghai ZJ Bio-Tech Co ranks #154 out of 805 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Shanghai ZJ Bio-Tech Co has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai ZJ Bio-Tech Co's Piotroski F-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Shanghai ZJ Bio-Tech Co ranks #154 out of 805 companies for Piotroski F-Score. This places Shanghai ZJ Bio-Tech Co in the top 19% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Shanghai ZJ Bio-Tech Co's value of 6 is 20% above this benchmark. Historically, Shanghai ZJ Bio-Tech Co's own Piotroski F-Score has ranged from 2.00 to 7.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Shanghai ZJ Bio-Tech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Devices & Instruments company?
The median Piotroski F-Score among Medical Devices & Instruments companies is 5.00, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai ZJ Bio-Tech Co's current Piotroski F-Score of 6 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Shanghai ZJ Bio-Tech Co and its competitors. For the Medical Devices & Instruments industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai ZJ Bio-Tech Co's current Piotroski F-Score is 6, which is 20% above median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai ZJ Bio-Tech Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai ZJ Bio-Tech Co (SHSE:688317) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥9.94, compared to a current price of ¥15.68 — trading 57.7% above its estimated fair value. The current Piotroski F-Score is 6, which is 20% above median its 10-year median of 5.00 and 20% above the Medical Devices & Instruments industry median of 5.00. Shanghai ZJ Bio-Tech Co's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Shanghai ZJ Bio-Tech Co (SHSE:688317), the current Piotroski F-Score is 6 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai ZJ Bio-Tech Co (SHSE:688317) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai ZJ Bio-Tech Co stock appears to be overvalued. The current stock price of ¥15.68 is trading 57.7% above its estimated GF Value™ of ¥9.94. GuruFocus considers Shanghai ZJ Bio-Tech Co to be Significantly Overvalued.

Key valuation signals for SHSE:688317:

  • Piotroski F-Score: 6 (20% above median its 10-year median of 5.00)
  • GF Value™: ¥9.94 vs. price of ¥15.68 (57.7% above fair value)
  • GF Score™: 68/100 with 2 warning signs
  • Industry Position: 20% above the Medical Devices & Instruments median (#154 of 805)

No single metric tells the full story. See the SHSE:688317 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shanghai ZJ Bio-Tech Co Business Description

Address No. 588 Xinjun Ring Road, Building 26, Pujiang Hi-Tech Park, Caohejing Development Zone, Shanghai, CHN
Shanghai ZJ Bio-Tech Co Ltd is engaged in research and development, production and sales of genetic diagnostic reagents and instruments and equipment. The rapid real-time fluorescent PCR diagnostic test reagents developed by the company are mainly used in clinical medicine, public health emergencies, entry-exit inspection and quarantine, food inspection, animal husbandry, aquaculture and other fields.
68GF Score

Get the complete analysis for SHSE:688317

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥15.68
Price
¥9.94
GF Value